Furthermore, NSCLC cancer patients responding to nivolumab had ~1.5-fold increase in 89Zr-nivolumab uptake in the tumor compared to non-responders, indicating PD-1 imaging can serve as a predictive tool for response to immunotherapy. Here, PDCD1 is linked to non-small cell lung carcinoma.